Rituximab in non-systemic vasculitic neuropathy: a single-center experience.

Felix KohleGilbert WunderlichGereon R FinkMichael SchroeterHelmar C LehmannChristian Schneider

Published in: Journal of neurology (2024)

Anti-CD20 therapy might be an alternative in NSVN patients requiring further treatment escalation or treatment switch due to side effects of corticosteroids or cyclophosphamide.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
low dose
clinical trial
stem cells